Sentence examples for trials requirements from inspiring English sources

A decision tree diagram highlighting critical decision points for selecting measures to meet varying clinical trials requirements has also been provided.

The masking procedures fulfilled the Consolidated Standards of Reporting Trials requirements for a double-masked trial.

Further measures to re-tool the clinical trials requirements for new antibiotics have recently been tabled by representatives of the pharmaceutical industry still active in antibiotics research [ 14].

These multicentre trials included similar end points, but during the trials requirements with respect to documentation of response, toxicity, QL and PSA measurements (Schmid et al, 2003) have evolved.

It was agreed that M&S was important in helping understand a new disease area and how regulatory requirements (e.g., the suitability of endpoints, populations in early- and late-stage trials, requirements for registration, and label claims) determine the feasibility for clinical development of a new compound.

Rose next had Lovett ride to the center of the arena and perform four spinning turns, a trials requirement.

They added that clinical trial requirements would make liquid nicotine commercially unviable, and are pressing for the European Union not to adopt new regulations.

All records were de-identified and only the range of each patient's age was documented, as per clinical trial requirements in The Netherlands.

In company news, Connectics plummeted 79%, after the drugmaker said that it would not seek FDA approval for relaxin, a treatment for the skin disease scleroderma, because it failed to meet Phase III trial requirements.

"Regulatory agencies like the FDA are contributing to the problem with a constant barrage of clinical trial requirements that make it harder, slower and more costly to develop antibiotics.” Another bad guy: "The National Institutes of Health was for many years [biased] against funding antibiotic research.”.

Since generic drugs are clinically identical versions of drugs already approved by the FDA, the FDA's clinical trial requirements before Hatch-Waxman did little more than deter generic manufacturers from selling their products in the United States, thus allowing name brands to maintain market monopolies years after their patent protections expired.